Symmetrel

Dyskinesias, Parkinson Disease, Extrapyramidal Disorders + 5 more
Treatment
11 FDA approvals
20 Active Studies for Symmetrel

What is Symmetrel

AmantadineThe Generic name of this drug
Treatment SummaryAmantadine is a medication used to prevent and treat influenza A. It can also be used to treat Parkinson's disease, involuntary muscle movements, and nerve pain caused by shingles. It works by increasing the production of dopamine in the brain and blocking its uptake, although the exact mechanism of action is not fully understood.
Symmetrelis the brand name
image of different drug pills on a surface
Symmetrel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Symmetrel
Amantadine
1976
103

Approved as Treatment by the FDA

Amantadine, also called Symmetrel, is approved by the FDA for 11 uses like Parkinsonism and Extrapyramidal Disorders .
Parkinsonism
Helps manage Parkinsonism
Extrapyramidal Disorders
Dyskinesia
Used in combination with other therapies
Parkinson's Disease (PD)
Helps manage Parkinson's Disease (PD)
prophylaxis of Influenza A virus infection
influenza A virus
Dyskinesias
Used in combination with other therapies
Pharmacotherapy
Used in combination with other therapies
Parkinson Disease
Helps manage Parkinsonism
Parkinson Disease
Used in combination with other therapies
Parkinson's Disease
Helps manage Parkinson's Disease (PD)

Effectiveness

How Symmetrel Affects PatientsAmantadine is an antiviral drug that can also be used to treat Parkinson's disease, usually in combination with L-DOPA. It is made from a similar drug called rimantadine and its exact effects are not known. It has been shown to increase the amount of dopamine in the brain, but it does not have anticholinergic properties.
How Symmetrel works in the bodyThe exact way this drug works against Parkinson's Disease is unknown, but it seems to work by increasing the amount of dopamine in the brain. It also blocks certain receptors in the brain related to nerve signals. The way it works against viruses is different; it stops a viral protein called M2 from working, which is necessary for the virus to spread.

When to interrupt dosage

The suggested dose of Symmetrel is dependent on the diagnosed affliction, such as influenza A virus, Restless Legs Syndrome (RLS) and Parkinson's Disease. The amount of dosage is based on the technique of delivery (e.g. Capsule - Oral or Oral), as detailed in the table below.
Condition
Dosage
Administration
Dyskinesias
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Parkinson Disease
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
prophylaxis of Influenza A virus infection
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Parkinson Disease
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Pharmacotherapy
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
influenza A virus
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Parkinson's Disease
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Extrapyramidal Disorders
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Symmetrel Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Amantadine may interact with Pulse Frequency
There are 20 known major drug interactions with Symmetrel.
Common Symmetrel Drug Interactions
Drug Name
Risk Level
Description
Adenovirus type 7 vaccine live
Major
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Amantadine.
Anthrax vaccine
Major
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Amantadine.
BCG vaccine
Major
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Amantadine.
Bacillus calmette-guerin substrain connaught live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amantadine.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Amantadine.
Symmetrel Toxicity & Overdose RiskTaking too much amantadine can be fatal, with the lowest reported lethal dose being 2 grams. Some of the potential side effects of an overdose include irregular heartbeats, difficulty breathing, reduced kidney function, insomnia, anxiety, aggressive behavior, confusion, delirium, hallucinations, lethargy, seizures, and a fever.
image of a doctor in a lab doing drug, clinical research

Symmetrel Novel Uses: Which Conditions Have a Clinical Trial Featuring Symmetrel?

340 active investigations are underway to assess the potential of Symmetrel for treating Post-Encephalitic Parkinsonism, Parkinsonism and Chorea.
Condition
Clinical Trials
Trial Phases
Pharmacotherapy
0 Actively Recruiting
influenza A virus
2 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Parkinson Disease
0 Actively Recruiting
Extrapyramidal Disorders
0 Actively Recruiting
Dyskinesias
0 Actively Recruiting
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
prophylaxis of Influenza A virus infection
0 Actively Recruiting
Parkinson Disease
0 Actively Recruiting

Symmetrel Reviews: What are patients saying about Symmetrel?

4.3Patient Review
2/23/2010
Symmetrel for Fatigue associated with Multiple Sclerosis
I was prescribed this for mental fatigue because of my MS. I've started to become really hypeverbal an hour after taking the dose, twice a day. I also have dysphasia and don't know if it's symmetrical or from the MS. Additionally, I've been itching all over my back--but that could just be dry skin. Another thing is that I haven't had the flu since starting this medication, but I take fiber daily for colitis so who knows if that also keeps me healthy? Anyway, diarrhea is rare for me--just a lot of regular bowel movements............MS spasms or what?
2.7Patient Review
2/7/2008
Symmetrel for A Type of Flu - Influenza A
I'm sorry, but I didn't notice any difference.
2.7Patient Review
6/19/2010
Symmetrel for A Type of Flu - Influenza A
The dizziness this caused was a bit of a problem, but my condition did improve while taking it.
2Patient Review
3/10/2011
Symmetrel for Parkinson's Disease
I haven't had great results with amanadine. I experience chills, fatigue, runny eyes and nose, difficulty sleeping, and heartburn.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about symmetrel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Symmetrel prescribed for?

"This medication is used to prevent or treat influenza A. If you have been infected with the flu, this medication may help make your symptoms less severe and shorten the time it will take you to get better."

Answered by AI

How does amantadine make you feel?

"Some people may experience agitation, irritability, or other abnormal behaviors when taking Amantadine. Additionally, it may cause some people to have suicidal thoughts or tendencies, or to become more depressed. If you experience sudden or strong feelings, such as feeling nervous, angry, restless, violent, or scared, be sure to tell your doctor."

Answered by AI

What type of drug is Symmetrel?

"Symmetrel is a prescription medicine that is used to treat the symptoms of Influenza A and Parkinson disease. Symmetrel can be used by itself or with other medications. Symmetrel belongs to a class of drugs that are called Antiparkinson Agents and Dopamine Agonists; Antivirals, Influenza."

Answered by AI

What is the drug amantadine used to treat?

"Amantadine is a medicine used to treat [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) and its symptoms, including dyskinesia. It may be given alone or in combination with other medicines for Parkinson's disease."

Answered by AI

Clinical Trials for Symmetrel

Image of AFC Trussville in Trussville, United States.

Metrix Respiratory Panel Test for COVID-19 and Flu

Any Age
All Sexes
Trussville, AL
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix Respiratory Panel Test for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory syncytial virus, and Rhinovirus in anterior nares (AN) swab samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, and Rhinovirus.
Waitlist Available
Has No Placebo
AFC TrussvilleBrad W Killingsworth, M.A.Aptitude Medical Systems
Have you considered Symmetrel clinical trials? We made a collection of clinical trials featuring Symmetrel, we think they might fit your search criteria.Go to Trials
Image of Centre for Brain and Mind, Western University in London, Canada.

Cognitive Cueing + Video Intervention for Parkinson's Disease

40 - 99
All Sexes
London, Canada
The goal of this clinical trial is to learn if cognitive cueing (eg., prompting individuals to think about taking big-long steps while walking), either as a stand- alone intervention or combined with a personalized gait training video, can improve gait (walking), mobility, and balance confidence for individuals with Parkinson's Disease. The main questions it aims to answer are: 1. Does focusing on cognitive cues while walking improve gait, mobility, and balance confidence for individuals with Parkinson's Disease? 2. Does incorporating a personalized gait training video alongside cognitive cueing lead to amplified improvements in gait, mobility, and balance confidence for individuals with Parkinson's Disease? Researchers will compare how gait, mobility, balance confidence and quality of life change over time for participants when they practice walking with and without a cognitive cue alone, and when they practice with using a personalized gait training video. The researchers are also interested in how participation in this trial will affect quality of life and conscious attention to gait. Participants will * Complete walking trials on an instrumented mat that records data on their walking ability. These trials will be undertaken without a cognitive cue and while participants mentally rehearse a series of 3 cognitive cues (Take big long steps; Walk heel-toe; Stand up straight). * Be informed about which of the 3 cues best improved their walking and will receive a personalized gait training video for at home practice. * Complete online surveys that ask questions about their Parkinson's Disease, mobility, balance confidence quality of life and conscious attention to gait. * Visit the research facility 3 to 4 times during the study to have their gait (walking), mobility, balance confidence, quality of life and conscious attention to gait assessed and reassessed. * Practice both with and without their personalized video at home and keep a diary to record their practice sessions * Participate in a brief interview to discuss their experiences with the training and their perceptions of the effectiveness of cognitive cues and video-recorded feedback
Waitlist Available
Has No Placebo
Centre for Brain and Mind, Western University
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Have you considered Symmetrel clinical trials? We made a collection of clinical trials featuring Symmetrel, we think they might fit your search criteria.Go to Trials
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Image of San Francisco VA Medical Center, San Francisco, CA in San Francisco, United States.

Ketamine for Depression in Parkinson's Disease

40 - 80
All Sexes
San Francisco, CA
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Phase 2
Recruiting
San Francisco VA Medical Center, San Francisco, CAEllen R Bradley, MD
Have you considered Symmetrel clinical trials? We made a collection of clinical trials featuring Symmetrel, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security